Individualized short-term therapy for adolescents impaired by ADHD despite previous routine care treatment (ESCAdol) - a randomized controlled trial within the consortium ‘ESCAlife’

Individualized short-term therapy for adolescents impaired by ADHD despite previous routine care treatment (ESCAdol) - a randomized controlled trial within the consortium ‘ESCAlife’ - ESCAadol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00008974

Enrollment

160

Registered

2015-12-28

Start date

2016-01-14

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit-/hyperactivity disorder (ADHD) F90

Interventions

Group 1: Individualised Modular Treatment Program (IMTP) The individualised modular treatment program as a focused short-term cognitive behavioural intervention consists of 10 weekly sessions à 60 mi

Eligibility

Sex/Gender

All

Age

12 Years to 17 Years

Inclusion criteria

Inclusion criteria: - ADHD according to DSM-5 criteria; diagnosis established by clinician-rated ADHD-Checklist (DCL-ADHS) - patient has been in ADHD routine care for a minimum of 6 months -no sufficient benefit from previous interventions developed for the treatment of ADHD children or ADHD adults (insufficient benefit defined as significant impairment by ADHD and/or co-morbid symptoms: CGI-S > 4) - patients and primary caregiver speak sufficient German

Exclusion criteria

Exclusion criteria: - IQ < 80 - comorbidity: pervasive developmental disorder, schizophrenia, bipolar disorder, severe depressive episode - need for inpatient treatment - after TAU-Phase co-treatment including: a) intensive psychotherapies on a biweekly or more intense basis or b) medication which is not constant or not licensed for the treatment of ADHD and co-morbid conditions

Design outcomes

Primary

Measure	Time frame
Change in blinded clinician-rated ADHD-Checklist (DCL-ADHS) scores between T2 (pre-intervention) and T3 (post-Intervention after 3 month)	—

Secondary

Measure	Time frame
Change from T2 (pre-intervention) to T3 (post-intervention) in impairment scores on the Clinical Global Impression Scale (CGI; clinician-rated), ADHD symptoms (SBB-ADHS, FBB-ADHS; patient-, parent- and teacher-rated), symptoms of oppositional-defiant and conduct disorder (SBB-SSV, FBB-SSV, clinical interview DCL-SSV; patient-, parent- and teacher- and clinician-rated), ADHD-related functional impairment (WFIRS-P; parent-rated), internalizing and externalizing symptoms (CBCL; parent-rated),- quality-of-life (KIDSCREEN-10; patient- and parent-rated) and parenting (FZEV, FPNE, VER; parent-rated).	—

Measure

Time frame

Change from T2 (pre-intervention) to T3 (post-intervention) in impairment scores on the Clinical Global Impression Scale (CGI; clinician-rated), ADHD symptoms (SBB-ADHS, FBB-ADHS; patient-, parent- and teacher-rated), symptoms of oppositional-defiant and conduct disorder (SBB-SSV, FBB-SSV, clinical interview DCL-SSV; patient-, parent- and teacher- and clinician-rated), ADHD-related functional impairment (WFIRS-P; parent-rated), internalizing and externalizing symptoms (CBCL; parent-rated),- quality-of-life (KIDSCREEN-10; patient- and parent-rated) and parenting (FZEV, FPNE, VER; parent-rated).

—

Countries

Germany

Contacts

Public ContactMarcel Romanos

Universiitätsklinikum WürzburgKlinik für Kinder- und Jugendpsychatrie, Psychosomatik u. Psychotherapie

romanos_m@ukw.de+ 49 931 201 78 010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 6, 2026